Chagas Disease in the U.S. (What United States Health Care Providers Need To Know About Chagas Disease)
COURSE NUMBER: WB4621
PROGRAM DESCRIPTION: This enduring activity will inform health care providers about Chagas disease including manifestations and transmission modes with example cases to relate to their own patient experiences.
At the conclusion of the session, the participant should be able to:
- Describe Chagas disease epidemiology.
- Describe the clinical manifestations of Chagas disease.
- Describe how to diagnose Chagas disease
- Describe the treatment options for Chagas disease.
- Using information presented in a case study demonstrate how to manage a patient with Chagas disease.
- Describe the importance of the health care team to address Chagas disease in U.S. patients.
Paul T. Cantey, MD, MPH, Parasitic Diseases Branch Chief, CDC, Center for Global Health, Division of Parasitic Diseases and Malaria
Susan P. Montgomery, DVM, MPH, Veterinary Medical Officer/Epidemiology Team Lead, CDC, Center for Global Health, Division of Parasitic Diseases and Malaria, Parasitic Diseases Branch
ORIGINATION DATE: September 02, 2022
EXPIRATION DATE: September 02, 2024
TARGET AUDIENCE: Physicians; Registered Nurses; Nurses
PREREQUISITES: Medical background/knowledge
CONTACT INFORMATION: Division of Parasitic Disease and Malaria, Parasitic Diseases Branch (404) 718-4745
In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 1.0 nursing contact hours.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Cantey and Dr. Montgomery’s discussion of benznidazole and nifurtimox (Lampit®). They will be discussing use of these two drugs to treat adult patients.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.Launch Course
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WB4621- Chagas Disease in the U.S. (What United States Health Care Providers Need to Know About Chagas Disease) please visit TCEO and follow these 9 Simple Steps before 9/2/2024
FEES: No fees are charged for CDC’s CE activities.